{"product_id":"tirzepatide-5mg-5mg-5mg-3-month-bundle","title":"Tirzepatide – 3-Month Supply – 503A Compounded","description":"\u003cdiv class=\"relax-consultation-fallback\"\u003e\n\u003cp\u003eAn in-person consultation with a RELAX specialist is required to discuss this product. Availability depends on clinical suitability and any applicable prescription requirements.\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"button button--secondary\" href=\"tel:+12153451100\"\u003eCall us\u003c\/a\u003e   \u003ca class=\"button\" href=\"https:\/\/booking.mangomint.com\/163230\"\u003eMake an appointment\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\u003ch3\u003e5mg 5mg 5mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 5mg and 5mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e5mg 5mg 10mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 5mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e5mg 10mg 10mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 5mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003eStarter: 5mg, 10mg, 15mg\/mL\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as an already reconstituted, ready-to-use sterile aqueous solution in a 2 mL vial at Starter: 5mg, 10mg, 15mg\/mL. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e10mg 10mg 10mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 10mg and 10mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e10mg 10mg 15mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 10mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e10mg 15mg 15mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 15mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e10mg 15mg 20mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 10mg, 15mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e15mg 15mg 15mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 15mg and 15mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e15mg 15mg 20mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 15mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e15mg 20mg 20mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 20mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003eMaintenance: 20mg, 20mg, 20mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 20mg and 20mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e15mg 20mg 25mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 15mg, 20mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e20mg 20mg 25mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 20mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e20mg 25mg 25mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 25mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003eMaintenance: 25mg, 25mg, 25mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 25mg and 25mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e20mg, 25mg, 30mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 20mg, 25mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e25mg 25mg 30mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 25mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003e25mg 30mg 30mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 25mg, 30mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003ch3\u003eMaintenance: 30mg, 30mg, 30mg\u003c\/h3\u003e\u003cp\u003eA dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, with a fatty diacid moiety supporting weekly administration. The dual mechanism distinguishes it pharmacologically from single-agonist GLP-1 receptor agonists.\u003cbr\u003eSupplied as three already reconstituted, ready-to-use sterile aqueous solution vials of 2 mL, dosed in sequence at 30mg, 30mg and 30mg. No reconstitution or mixing is required before administration. For subcutaneous administration. Dispensed as a 3-month course totalling 84 days of therapy, supplied as the vials listed for the selected strength option.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVial size listed by supplier\u003c\/strong\u003e 2 mL\u003c\/p\u003e\u003cp class=\"relax-supplier-availability\"\u003e\u003cstrong\u003eSupplier availability\u003c\/strong\u003e · In stock\u003c\/p\u003e\u003cdiv class=\"relax-native-related\"\u003e\n\u003ch2\u003eSimilar products\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"\/products\/tirzepatide-5mg-ml\"\u003eTirzepatide – 1-Month Supply – 503A Compounded\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"\/products\/semaglutide-1mg-1mg-1mg-3-month-bundle\"\u003eSemaglutide – 3-Month Supply – 503A Compounded\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"ProPepMD","offers":[{"title":"5mg 5mg 5mg \/ 2 mL","offer_id":50984994406593,"sku":"RXR-53142433-dmp-tirz-3-month-injection-5mg5mg5mg","price":352.0,"currency_code":"USD","in_stock":true},{"title":"5mg 5mg 10mg \/ 2 mL","offer_id":50984994439361,"sku":"RXR-3E3E7C5A-dmp-tirz-3-month-injection-5mg5mg10mg","price":431.2,"currency_code":"USD","in_stock":true},{"title":"5mg 10mg 10mg \/ 2 mL","offer_id":50984994472129,"sku":"RXR-969295BA-dmp-tirz-3-month-injection-5mg10mg10mg","price":501.6,"currency_code":"USD","in_stock":true},{"title":"Starter: 5mg, 10mg, 15mg\/mL \/ 2 mL","offer_id":50984994504897,"sku":"RXR-E1264AD4-dmp-tirz-starter-3-mth-5mg10mg15mg-ml","price":526.24,"currency_code":"USD","in_stock":true},{"title":"10mg 10mg 10mg \/ 2 mL","offer_id":50984994537665,"sku":"RXR-D721C84C-dmp-tirz-3-month-injection-10mg10mg10mg","price":580.8,"currency_code":"USD","in_stock":true},{"title":"10mg 10mg 15mg \/ 2 mL","offer_id":50984994570433,"sku":"RXR-09A3C9B6-dmp-tirz-3-month-injection-10mg10mg15mg","price":668.8,"currency_code":"USD","in_stock":true},{"title":"10mg 15mg 15mg \/ 2 mL","offer_id":50984994603201,"sku":"RXR-12B46C22-dmp-tirz-3-month-injection-10mg15mg15mg","price":739.2,"currency_code":"USD","in_stock":true},{"title":"10mg 15mg 20mg \/ 2 mL","offer_id":50984994635969,"sku":"RXR-AD587D49-dmp-tirz-3-month-injection-10mg15mg20mg","price":748.0,"currency_code":"USD","in_stock":true},{"title":"15mg 15mg 15mg \/ 2 mL","offer_id":50984994668737,"sku":"RXR-36FD945B-dmp-tirz-3-month-injection-15mg15mg15mg","price":827.2,"currency_code":"USD","in_stock":true},{"title":"15mg 15mg 20mg \/ 2 mL","offer_id":50984994701505,"sku":"RXR-319B4C5E-dmp-tirz-3-month-injection-15mg15mg20mg","price":902.88,"currency_code":"USD","in_stock":true},{"title":"15mg 20mg 20mg \/ 2 mL","offer_id":50984994734273,"sku":"RXR-2DB1685E-dmp-tirz-3-month-injection-15mg20mg20mg","price":943.36,"currency_code":"USD","in_stock":true},{"title":"Maintenance: 20mg, 20mg, 20mg \/ 2 mL","offer_id":50984994767041,"sku":"RXR-21B7CD1B-dmp-tirz-maintenance-20mg-x-3-vials","price":976.8,"currency_code":"USD","in_stock":true},{"title":"15mg 20mg 25mg \/ 2 mL","offer_id":50984994799809,"sku":"RXR-07713D06-dmp-tirz-3-month-injection-15mg20mg25mg","price":1012.0,"currency_code":"USD","in_stock":true},{"title":"20mg 20mg 25mg \/ 2 mL","offer_id":50984994832577,"sku":"RXR-5E375E44-dmp-tirz-3-month-injection-20mg20mg25mg","price":1064.8,"currency_code":"USD","in_stock":true},{"title":"20mg 25mg 25mg \/ 2 mL","offer_id":50984994865345,"sku":"RXR-EAC472D5-dmp-tirz-3-month-injection-20mg25mg25mg","price":1091.2,"currency_code":"USD","in_stock":true},{"title":"Maintenance: 25mg, 25mg, 25mg \/ 2 mL","offer_id":50984994898113,"sku":"RXR-457D48E1-dmp-tirz-maintenance-25mg-x-3-vials","price":1144.0,"currency_code":"USD","in_stock":true},{"title":"20mg, 25mg, 30mg \/ 2 mL","offer_id":50984994930881,"sku":"RXR-898296F1-dmp-tirz-20mg25mg30mg","price":1144.0,"currency_code":"USD","in_stock":true},{"title":"25mg 25mg 30mg \/ 2 mL","offer_id":50984994963649,"sku":"RXR-6A40A2B3-dmp-tirz-3-month-injection-25mg25mg30mg","price":1205.6,"currency_code":"USD","in_stock":true},{"title":"25mg 30mg 30mg \/ 2 mL","offer_id":50984994996417,"sku":"RXR-6E146591-dmp-tirz-3-month-injection-25mg30mg30mg","price":1293.6,"currency_code":"USD","in_stock":true},{"title":"Maintenance: 30mg, 30mg, 30mg \/ 2 mL","offer_id":50984995029185,"sku":"RXR-74618C67-dmp-tirz-maintenance-30mg-x-3-vials","price":1304.16,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0809\/7490\/5537\/files\/propepmd-tirzepatide-5mg-5mg-5mg-3-month-bundle-1.png?v=1795066856","url":"https:\/\/belladermabocaspa.com\/products\/tirzepatide-5mg-5mg-5mg-3-month-bundle","provider":"Bella Derma Boca Spa","version":"1.0","type":"link"}